The Prospects for DANANIMAB as a Treatment for Alzheimer's Disease

Dr. Rabinovich: This is a really significant advance that brings a lot of hope, but I think the limitations of the monoclonal antibodies are also becoming clear with multiple drugs now showing very consistently 25 to 35% slowing of clinical decline. So for sure, there's going to be, as you mentioned, challenges with access and equity, but at least one potential bright spot is that this may not need to be a treatment that goes on indefinitely.